Skip to main content
. 2015 May 20;6(25):21064–21073. doi: 10.18632/oncotarget.4222

Figure 2. DRFS of RAD54B high and low groups.

Figure 2

A. Kaplan–Meier survival analyses of 108 stage I–III CRC patients in the training set revealed that the RAD54B high group had inferior DRFS compared with the low group (P = 0.0013). B. Kaplan–Meier survival analyses of 71 stage I–III CRC patients in the validation set revealed that the RAD54B high group had inferior DRFS compared with the low group (P = 0.024).